Latest News and Press Releases

60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials

60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.

60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.

Adtelligent earns a 2025 Inc. Power Partner Award for innovation and trusted collaboration in global adtech.

For the second year, Inc. has named Truepic a 2025 Power Partner award winner for its ongoing innovation and for providing Visual Risk intelligence.

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.

60 Degrees Pharma unveils “B-FREE” Phase 2 trial for chronic babesiosis, engaging patients in naming and supporting Lyme research groups.

60 Degrees Pharma (Nasdaq: SXTP) CEO Dr. Geoff Dow to present at HCW Conference Tuesday, Sept 9, 3:30 PM ET. Live webcast link available.

Amid rising uncertainty about higher ed’s value, CourseCompare’s ROE Index delivers Canada’s first data-driven benchmark of programs that pay off fastest.

60 Degrees Pharma CEO Dr. Geoff Dow will present Sept 10 at HCW 27th Global Investment Conference; webcast and replay available on company’s investor site.